Real world efficacy of dose-reduced capmatinib and tepotinib for advanced MET exon 14–skipping+ NSCLC.
Authors: Rajaa Mohamed Salih, Julia Berg, Page Widick, Deepa Rangachari, Paul Joseph Hesketh, Karl John D'Silva, Daniel Botelho Costa, AJ Piper-Vallillo